Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients.
about
Iron metallodrugs: stability, redox activity and toxicity against Artemia salinaIron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects.Transfusion of older stored blood worsens outcomes in canines depending on the presence and severity of pneumonia.Iron metabolism in hemodialyzed patients - a story half told?A transgenic mouse model expressing exclusively human hemoglobin E: indications of a mild oxidative stress.Non transferrin bound iron: nature, manifestations and analytical approaches for estimationDrug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.Short-term benefits and risks of intravenous iron: a systematic review and meta-analysis.Safety issues with intravenous iron products in the management of anemia in chronic kidney diseaseThe Labile Side of Iron Supplementation in CKDFerric saccharate induces oxygen radical stress and endothelial dysfunction in vivo.Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.Hypoxia biomarkers, oxidative stress, and circulating microparticles in pediatric patients with thalassemia in Upper Egypt.Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels.Evaluation of oxidative stress after repeated intravenous iron supplementation.Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease.Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.In Vitro Release Kinetics and Transferrin Saturation Study of Intravenous Iron Sucrose Entrapped in Poly(ethylene glycol)-Assisted Silica Xerogel.Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
P2860
Q28545763-3E1CBB6C-A1B3-4F89-A62E-39FA0CFF777FQ34333986-8DDB927E-2F8A-465E-B99E-F2CB6C726987Q34429446-3F234C9F-ADCC-4817-8B67-88EB8DC4FD5BQ34974326-1535CD94-ADFE-498C-8AFE-86D1A4A5E558Q35848216-8A1C0A8E-4BD1-448C-A158-18225B41A1A4Q36336362-94F4ADEC-E9E8-454D-95E9-EBCA3EC311E7Q36577123-DCB1290E-9795-42A3-B2DD-2E0A19ECFB93Q36946004-57E6673C-7EB5-4F15-8A62-63103630367AQ37161960-11885493-E268-4A21-88AA-7BF4D0A28961Q38496987-BB4A1210-5F0D-42CE-BCF5-59DCF9A9B0E8Q43910618-956C5172-E2E8-47C4-9D9D-31770FC5E444Q43910629-FE4657E7-5978-4720-AE93-354CB9157949Q45901373-1BB9A6EE-29F3-4204-A462-FAE0DDBBF321Q46546922-322C7CA5-EE90-4DA7-94FD-6A1820A6570AQ46548091-A9B9D1A4-CE78-42DE-A6B7-3BD0E7114CB2Q46705821-6A5FAC89-A41A-48C7-BF12-186A8E8E6B5BQ48660551-845BD3AC-2929-4021-A164-225A5F14D038Q51599918-E7EA4CD2-EFEA-47B8-A252-3CE29CB4DB47Q53102532-D5496251-852C-4344-B50F-CEBE88B54E4A
P2860
Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Labile iron in parenteral iron ...... und iron in dialysis patients.
@en
Labile iron in parenteral iron ...... und iron in dialysis patients.
@nl
type
label
Labile iron in parenteral iron ...... und iron in dialysis patients.
@en
Labile iron in parenteral iron ...... und iron in dialysis patients.
@nl
prefLabel
Labile iron in parenteral iron ...... und iron in dialysis patients.
@en
Labile iron in parenteral iron ...... und iron in dialysis patients.
@nl
P2093
P2860
P1476
Labile iron in parenteral iron ...... und iron in dialysis patients.
@en
P2093
Cabantchik ZI
Espósito BP
P2860
P356
10.1046/J.1365-2362.2002.0320S1042.X
P478
32 Suppl 1
P577
2002-03-01T00:00:00Z